KR102212625B1 - Composition comprising Mentha Arvensis Extract for anti-aging or anti-inflammation - Google Patents

Abstract

In the present specification, as a composition for external application for skin containing a peppermint extract as an active ingredient, IL-1a (NM_000575), IL-1B (NM_000576), which are genes in skin cells whose expression levels are affected by stimulants causing inflammation or aging, An anti-aging composition and an anti-inflammatory composition for controlling the expression level of one or more selected from the group consisting of PTGS2 (NM_000963) and XDH (NM_000379) to a normal level are disclosed.
By using the anti-aging composition and the anti-inflammatory composition, it is possible to reduce damage to skin cells by returning the gene expression level changed by the stimulator causing inflammation or aging to a normal level.

Description

Composition comprising Mentha Arvensis Extract for anti-aging or anti-inflammation {Composition comprising Mentha Arvensis Extract for anti-aging or anti-inflammation}

Anti-aging and anti-inflammatory compositions are disclosed herein. In more detail, compared to normal skin cells, mentha herb ( Mentha) significantly changes the biomarker, which is a skin cell gene whose expression level is changed by aging and inflammation, to reduce aging and inflammation of skin cells. Arvensis ) A composition comprising an extract is disclosed.

These days, artificial temperature control of cooling/heating according to changes in the environment or lifestyle patterns, various stresses occurring in social life and skin stress due to environmental pollution, frequent cleansing according to makeup habits, and natural skin according to age increase Inflammation and skin aging are occurring.

In addition, excessive physical and chemical stimuli, ultraviolet rays, and stress from the outside degrade the normal function of the skin and promote phenomena such as loss of elasticity, keratinization, wrinkle formation, and inflammation.In particular, ultraviolet rays, yellow dust or dust stimulate aging. It is a source of irritation or irritation.

Interleukin 1 is classified as a senescence-associated secretory phenotype (SASP).In particular, interleukin 1a and 1b (IL-1a and IL-1b) are representative senescence markers and are involved in cellular senescence. It is known (see Non-Patent Document 1). It is also known that IL-1a, IL-1b and PTGS2 are involved in skin inflammation, and XDH represents oxidative stress induced by prolonged exposure to irritants, and as a result, is an indicator of exogenous skin aging (non- See Patent Document 2). In addition, it is also known that PTGS2 (=COX-2) and IL-1a are expressed in skin cells exposed to irritants in relation to skin inflammation (see Non-Patent Document 3), and xanthine dehydrogenase (XDH) is As an indicator of oxidative stress, it is also known to be involved in skin aging. The above documents are incorporated by reference in their entirety as part of this specification.

Jean-Philippe Coppe, et al, "The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression", Annual Review of Pathology: Mechanisms of Disease, volume 5, 2010. Kim, H.J., et al, "Transcriptome analysis of airborne PM2.5-induced detrimental effects on human keratinocytes", Toxicology Letters 273, 26-35, 2017. Natalia D Magnani, et al, "Skin Damage Mechanisms Related to Airborne Particulate Matter Exposure", toxicological sciences, 149(1), 2016, 227-236.

Accordingly, the present inventors have found that the irritant causing inflammation or aging has a detrimental effect on the skin, and by this effect, it affects the expression of skin cell genes, resulting in symptoms such as skin cell aging and inflammation.

Accordingly, in one aspect, the present invention aims to provide an anti-aging composition and an anti-inflammatory composition.

In order to achieve the above object, in one aspect, the present invention is a composition comprising a peppermint herb extract as an active ingredient, IL-1a, a gene in skin cells whose expression level is affected by a stimulator causing inflammation or aging ( NM_000575), IL-1B (NM_000576), PTGS2 (NM_000963), XDH (NM_000379) It provides an anti-aging composition and an anti-inflammatory composition for controlling the expression level of one or more selected from the group consisting of a normal level.

In one aspect, by using the anti-aging composition and the anti-inflammatory composition provided by the present invention, it is possible to reduce damage to skin cells by returning the gene expression level changed by inflammation or aging stimulation to a normal level.

FIG. 1 shows the cell viability by the stimulus treatment, where ADSP represents yellow dust as Asian dust storm particles, and PM10 (Particulate matter 10) represents fine dust having a particle size of 10 μm. , PM2.5 (Particulate matter 2.5) represents fine dust with a particle size of 2.5㎛.
2A shows that the mRNA expression level of the IL-1A gene is increased in skin cells to which stimulation causing inflammation or aging is applied.
2B shows that the mRNA expression level of the IL-1B gene is increased in skin cells to which stimulation causing inflammation or aging is applied.
Figure 2c shows that the mRNA expression level of the PTGS2 gene is increased in skin cells to which stimulus causing inflammation or aging is applied.
Figure 2d shows that the mRNA expression level of the XDH gene is increased in skin cells to which stimulation causing inflammation or aging is applied.
Figure 3a shows that the expression level of the IL-1A gene changed in the skin cells to which the stimulation causing inflammation or aging is applied returns to a normal level by treatment with a peppermint extract.
Figure 3b shows that the expression level of the IL-1B gene changed in the skin cells to which the stimulation causing inflammation or aging is applied returns to the normal level by treatment with the peppermint extract.
Figure 3c shows that the expression level of the PTGS2 gene changed in the skin cells to which the stimulation causing inflammation or aging is applied returns to a normal level by treatment with a peppermint extract.
Figure 3d shows that the expression level of the XDH gene changed in skin cells to which stimulus causing inflammation or aging is applied returns to a normal level by treatment with a peppermint extract.

Hereinafter, the present invention will be described in detail.

Mentha Arvensis belongs to the perennial plant roots of the Lamiaceae family of the mosquito plant, and is also called nocturnal flavor, beonhachae, indancho, and gourd. Peppermint is characterized by a refreshing, transparent and refreshing flavor, and leaves and stems grown in a cool climate have a strong scent. It mainly contains menthol, giving off a unique scent, and also contains nutrients such as vitamins.

In one aspect of the invention, the composition comprises a peppermint extract.

In one aspect, leaves or stems of peppermint may be used, but is not limited thereto. In one embodiment, leaves of mint may be used.

In one aspect, the peppermint may be dried and pulverized.

"Peppermint" herein may include non-fermented mint or fermented mint. In one embodiment, the peppermint includes fermented peppermint leaves.

In one aspect, the fermentation may include fermentation by adding microorganisms. Specifically, the genus Acetovacter sp . ) It may include fermentation by adding microorganisms. In one embodiment, fermentation is carried out by adding Acetovacter aceti .

Peppermint vinegar to which the microorganism is added may be specifically fermented at 22-30 °C for 24-72 hours. In one embodiment, the extract is fermented at 26° C. for about 48 hours.

In one aspect of the present invention, the peppermint may be extracted with a specific extraction solvent to form a peppermint extract.

In one aspect of the present invention, the peppermint extract may be prepared by extracting leaves or stems of peppermint with water or an organic solvent. Specifically, the leaves or stems of peppermint are selected from the group consisting of water, C ₁ -C ₆ anhydrous or aqueous lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane. It can be prepared by extraction with any one or more extraction solvents.

In one aspect, the mint extract may be extracted at room temperature.

In one aspect, the peppermint extract may be obtained by additionally performing one or more of filtration, concentration, separation or drying after being extracted with the extraction solvent. In particular, the mint extract may be subjected to one or more filtration processes, and in one embodiment, two filtration processes are performed.

In one embodiment, the separation process may include a centrifugation process.

Specifically, the extraction includes water, an anhydrous or hydrous lower alcohol of C ₁ -C ₆ , a polar solvent including acetone and butylene glycol, and ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform, and hexane. Any one or more of the low polarity solvents may be used as the solvent.

More specifically, the solvent may be a 50-90% aqueous ethanol solution, 60-80% or 65-75% ethanol aqueous solution. When the solvent is a 50-90% ethanol aqueous solution, the active ingredient can be effectively extracted from peppermint. In one embodiment, the solvent may be about 70% aqueous ethanol solution.

In one aspect, the extract may be concentrated under reduced pressure to an appropriate temperature in a distillation apparatus equipped with a cooling condenser after extraction.

However, the peppermint extract according to the present invention can be obtained by extraction by a conventional method in the art, and is not limited by the above-described method.

In one aspect of the present invention, in the composition, the composition may include a peppermint extract in an amount of 0.000001 to 30% by weight based on the total weight of the composition. When the content is 0.000001 to 30% by weight, the effect of caring for skin damage due to fine dust by the mint extract was excellent.

Specifically, 0.0000001 wt% or more, 0.0000005 wt% or more, 0.0000007 wt% or more, 0.0000009 wt% or more, 0.000001 wt% or more, 0.000002 wt% or more, 0.000004 wt% or more, 0.000006 wt% or more, 0.000008 wt% or more, 0.00001 weight % Or more, 0.00003% or more, 0.00005% or more, 0.00007% or more, 0.00009% or more, 0.0001% or more, 0.0003% or more, 0.0005% or more, 0.0007% or more, 0.0009% or more, 0.001% or more % Or more, 0.01% or more, 0.1% or more, 1% or more, 3% or more, 5% or more, 7% or more, 9% or more, 10% or more, 13% or more, 15% % Or more, 17 wt% or more, 19 wt% or more, 21 wt% or more, 23 wt% or more, 25 wt% or more, 27 wt% or more, 29 wt% or more, 30 wt% or more, 31 wt% or more, 32% or less, 31% or less, 30% or less, 29% or less, 28% or less, 26% or less, 24% or less, 22% or less, 20% or less, 18% or less, 16% or less, 14% or less, 12% or less, 10% or less, 9% or less, 8% or less, 6% or less, 4% or less, 2% or less, 1% or less, 0.1 wt% or less, 0.09 wt% or less, 0.04 wt% or less, 0.01 wt% or less, 0.006 wt% or less, 0.001 wt% or less, 0.0009 wt% or less, 0.0007 wt% or less, 0.00005 wt% or less, 0.00003 wt% or less, 0.00001 wt% or less, 0.000009 wt% or less, 0.000007 wt% or less, 0.000005 wt% or less, 0.000003 wt% or less, 0.000001 wt% or less Below, 0.0000009 wt% or less, 0.0000007 wt% or less, 0.0000005 wt% or less, 0.0000003 wt% or less, 0.0000002 wt% or less, 0.0000001 wt% or less, 0.00000009 wt% or less, but is not limited thereto.

Another aspect of the invention includes anti-aging and anti-inflammatory uses of the compositions of the invention.

In one aspect, the present invention provides a composition for inhibiting inflammation or aging by controlling the expression level of a specific gene in skin cells damaged by inflammation or aging stimulation to a normal level.

In one aspect, specifically, in the present invention, genes in skin cells whose expression levels are affected by stimulation of inflammation or aging are IL-1a (NM_000575), IL-1B (NM_000576), PTGS2 (NM_000963), XDH (NM_000379), etc. Includes. The IL-1a (NM_000575), IL-1B (NM_000576), PTGS2 (NM_000963), XDH (NM_000379) are genes whose expression levels are increased by stimulation of inflammation or aging, so they are regulated to normal levels by inhibiting the expression levels of these genes. By doing so, it suppresses inflammation or aging of skin cells.

In one aspect, genes whose expression levels are increased by stimulation of inflammation or aging used in the present invention are shown in [Table 1]. In the table, Name means NCBI's genebank accession ID, Gene Symbol means the official gene symbol, and Gene title means the name of each gene.

Increase gene Name Gene
Symbol Gene title NM_000576 IL1B interleukin 1, beta NM_000575 IL1A interleukin 1, alpha NM_000963 PTGS2 Cyclooxygenase-2 (COX-2) NM_000379 XDH xanthine dehydrogenase

Analysis of the expression level of the gene or protein includes microarray, PCR, NGS (Nest Generation Sequencing; next-generation sequencing), Western blot, Northern blot, ELISA, radioimmunoassay, radioimmuno diffusion method, tissue immunostaining, immunoprecipitation analysis, etc. It can be analyzed using a variety of analysis methods known in the art.

In one aspect of the present invention, the composition may be a cosmetic composition, a pharmaceutical composition, or a health functional food composition.

The cosmetic composition includes, for example, various creams, lotions, various creams, lotions, and cosmetics such as skins, cleansing, face wash, soap, and beauty liquids.

In one aspect, the cosmetic to which the composition containing the peppermint extract of the present invention is added may take the shape of a solution, an emulsion, a viscous mixture, or the like.

That is, the cosmetic as an aspect of the present invention is not particularly limited in its formulation, and for example, emulsion, cream, lotion, essence, pack, gel, powder, makeup base, foundation, lotion, ointment, patch, essence, cleansing Formulations such as foam, cleansing cream, cleansing water, body lotion, body cream, body oil, body essence, shampoo, conditioner, body cleaner, soap, hair dye, spray, etc. may be mentioned.

In the cosmetic composition of each formulation, other ingredients other than the peppermint extract may be appropriately selected and blended by a person skilled in the art without difficulty according to the formulation or purpose of use of the other cosmetic.

In addition, the cosmetic as an aspect of the present invention may include a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingo lipids, and seaweed extract.

In one aspect, in the cosmetic composition of the present invention, in addition to the essential ingredients, other ingredients which are usually blended in the cosmetic may be blended as needed.

Other ingredients that may be added include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, Blood circulation accelerators, cold sensation agents, restrictors, and purified water.

In addition, the blending components that may be added are not limited thereto, and any of the above components can be blended within a range that does not impair the object and effect of the present invention.

In one aspect, the pharmaceutical composition comprising the peppermint extract of the present invention may further include a suitable carrier, excipient, and diluent commonly used in the manufacture of pharmaceutical compositions.

As the dosage form, the pharmaceutical composition containing the peppermint extract may include oral preparations such as tablets, capsules, powders or syrups, or external preparations such as ointments, gels, creams, patches or sprays according to a conventional method. It can be formulated and used in any form suitable for pharmaceutical preparations.

In general, it should be understood that the actual dosage of the active ingredient administered by the pharmaceutical composition should be determined in light of various related factors such as the severity of symptoms, the selected route of administration, the age, sex, weight and health status of the subject. In general, the dosage of the active ingredient may be 0.0001 mg/kg/day to 3000 mg/kg/day, for example, 10 mg/kg/day to 500 mg/kg/day.

In the health functional food composition as an aspect of the present invention, the health food is manufactured using nutrients that are easily deficient in daily meals or raw materials or ingredients (functional ingredients) having useful functions for the human body, and maintains the normal function of the human body Or it may refer to food that maintains and improves health through activation of physiological functions, but is not limited thereto. The health food may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc., but is not limited thereto and may be manufactured and processed in any form according to laws.

Specifically, the health drink composition is not particularly limited to other ingredients other than containing the compound as an essential ingredient in the indicated ratio, and may contain various flavoring agents or natural carbohydrates as an additional ingredient, such as a conventional beverage. Examples of natural carbohydrates are common sugars such as monosaccharide polysaccharide, cyclodextrin, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.

In general, it should be understood that the actual dosage of the active ingredient administered by the health functional food composition should be determined in light of various related factors such as the severity of symptoms, the selected route of administration, the age, sex, weight, and health status of the subject. . In general, the dosage of the active ingredient may be 0.0001 mg/kg/day to 1000 mg/kg/day, for example, 0.02 mg/kg/day to 6 mg/kg/day.

Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to examples. However, these examples are provided for illustrative purposes only to aid understanding of the present invention, and the scope and scope of the present invention are not limited by the following examples.

[Example 1] Preparation of mint extract

After preparing peppermint leaves and Acetovacter aceti, these were fermented at 26°C for 48 hours. And the fermented product was extracted at room temperature using an extraction solvent obtained by mixing purified water and ethanol in a volume ratio of 3:7, that is, 70% ethanol as an extraction solvent. After extraction at room temperature, primary filtration was performed to remove the solid material contained in the extract, and then the extract was concentrated to remove ethanol, and this was separated and purified. Then, after centrifugation and secondary filtration, the mixture was dried to obtain a mint extract.

[Example 2] Preparation of aging and anti-inflammatory stimulants

Fine dust was collected using a low volume air sampler (Sensidyne, Gillian, Low Volume Air Sampler, FL, USA), and the filter pack was sampled for about 24 hours by changing the filter and denude around 10 am on every measurement day. Was collected. For 28 days, fine dust was collected every day at Punghaji Station in Seoul (located in Cheoin-gu, Yongin-si, Gyeonggi-do, on the 6th floor of the dormitory of Hankuk University of Foreign Studies Research Center for Foreign Studies), and the measurement time is measured by starting the timer while turning on the vacuum pump and turning off the vacuum pump. The time was recorded. The sampling flow rate was 16.7 L/min, and the flow rate was measured with a flow meter (Model 4143, TSI Inc.) at the beginning of the measurement, and the flow rate was measured again at the end of the measurement. The weight of the Teflon filter in the filter pack was measured before and after sample collection. Before measuring the weight of the Teflon filter, put a constant weight in a desiccator (NIKKO, Japan) with a relative humidity of 40% for 24 hours, and then measure the weight twice on an electronic scale (DVG215CD, Ohaus) with 5 decimal places to calculate the average value. Recorded. Even after collecting the sample, the weight was measured twice in a desiccator for 24 hours before measuring the weight, and the mass concentration was calculated by comparing it with the weight measured before collection. The extraction of fine dust was carried out by soaking a Teflon filter in 1 mL of ethanol, adding 14 mL of DW, closing the lid while making the aerosol collection surface of the filter contact the water surface, and applying ultrasonic waves for 30 minutes with an ultrasonic cleaner. In order to minimize the error due to moisture in the filtration step, after completely removing moisture from the filter for 48 hours in a decicator, weigh the filter using an ultra-precise scale (Mettler Toledo Company) that can measure up to 0.1 mg. Weighed and weighed before and after extraction of the filter.

[Example 3] Cultivation of (normal human) keratinocyte line

(Normal person) keratinocyte cell line (Human normal epidermal keratinocytes) was then purchased from Lonza社(Lonza, Inc. Walkersville, Maryland material) 37 ℃ subcultured in a CO ₂ incubator (CO ₂ incubator), 5% CO Incubated under ₂ conditions. The cell culture medium was in accordance with Lonza's guidelines. KGM-2 bullet kit CC-4152 (KGM TM-2 Bullet kit, CC-4152) (ingredient: BPE (Bovine pituitary extract)), human epidermis growth in 500 ml of KBM-2 (KBMTM-2, CC-3103) medium Human epidermal growth factor (hEGF), Insulin, Hydrocortisone, Transferrin, Epinephrine, and Gentamicin Sulfate + Amphofericin-B (Gentamycin Suflate + Amphofericin-B: GA) -1000)) was added to the KGM-2 bullet kit CC-3107 (KGM TM-2 Bullet Kit, CC-3107).

[Example 4] (Normal human) keratinocyte treatment and cytotoxicity measurement

In order to confirm the cytotoxicity through fine dust treatment, an MTT experiment was performed using a (normal human) keratinocyte line by the method of Mossman et al. (J. Immunol. Methods, 65, 55-63, 1983).

Specifically, a 24-well plate was used and fine dust having a diameter of 2.5 μm obtained by collecting in Example 2 was dispersed in purified water to prepare a fine dust dispersion, and then 2.5 × 10 ^{5 in} the cell culture conditions of Example 3 Cells cultured under the condition of the number of well cells were treated with the fine dust dispersion and cultured for 24 hours, and then 5 mg/ml of MTT (3-4,5-dimethylthiazol-2,5-diphenyltetra zolium bromide) was mixed and 37 Incubated for an additional 3 hours at ℃. After that, the medium was removed and the formed formazan crystal was dissolved in 500 µl of DMSO. The lysate was transferred to a 96-well plate, aliquoted, and the OD value was measured at an absorbance of 540 nm. The measurement results are shown in FIG. 1.

As shown in Fig. 1, the concentration (IC20) value showing 80% viability against cytotoxicity by a dispersion in which fine dust of 2.5 micrometers or less is dispersed in the cell line is 12.5 μg/in the case of an aqueous extract of fine dust of 2.5 micrometers or less. It was ml.

[Example 5] Confirmation of cell gene change due to aging and inflammatory stimulation through Next Generation Sequencing

For RNA-sequencing data processing and analysis, reference was made to the general analysis steps developed by Trapnell et al. (2012). RNA-seq data quality was checked using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), and FASTX (http://hannonlab.cshl.edu/fastx_toolkit/) was used. Thus, base and adapter sequences with poor accuracy were removed. Thereafter, alignment was performed using Tophat (Trapnell et al., 2009) and human genome (hg19), and the data amount of each sample was confirmed using EVER-seq, renamed RSeQC (Wang et al., 2012). ). In addition, expression levels of transcripts were quantified using Cufflinks, and the levels of transcription were compared between samples treated with fine dust dispersion and normal samples (Trapnell et al., 2010). FDR adjusted p-value<0.05, a strict cutoff of ≥2.0 fold-change was applied to determine a gene that showed a significant difference in expression when the dispersion of fine dust having a diameter of 2.5 μm was treated. The measurement results are shown in the following [Table 2] and [FIG. 1A] to [FIG. 1D].

Increase gene Name Gene
Symbol Drainage change NM_000575 IL-1a 4.014605674 NM_000576 IL1B 11.31259177 NM_000963 PTGS2 2.284968542 NM_000379 XDH 2.57463302

[Example 6] Real-time RT-PCR quantification

The fine dust having a diameter of 2.5 μm extracted in Example 2 was treated with 12.5 μg of human normal keratin skin cells cultured in Example 3 in 1 ml of cell culture medium, and the primers of the genes shown in Table 3 below (applied biosystems) TaqMan® Primers) was used to measure the relative amount of mRNA expression. Peppermint extract was used as prepared in Example 1.

Increase gene Name Gene
Symbol TaqMan® primer NM_000575 IL-1a Hs00174092_m1 NM_000576 IL1B Hs01555410_m1 NM_000963 PTGS2 Hs00153133_m1 NM_000379 XDH Hs00166010_m1

After 24 hours of treatment with the peppermint extract in the medium at a concentration of 20 ppm, the culture medium was removed, and the cells were washed with 2 ml of Phosphate Buffered Saline (PBS), and then Trizol reagent (Invitrogen, Carlsbad, CA, USA) was used to isolate intracellular RNA. The isolated RNA was purified once more with QIAGEN's RNA kit (QIAGEN RNeasy kt, QIAGEN, Valencia, CA), and then Agilent's Bioanalyzer 2100 model instrument (Agilent 2100 BioAnalyzer, Agilent Technologies, Santa Clara, CA, USA). ) Was used to check the quality of RNA. CDNA was synthesized from the RNA using Invitrogen's Superscript Reverse Transcriptase (RT) kit, Invitrogen, Carlsbad, CA, and this was obtained by using the primers of [Table 3] in real time reverse transcription polymerase chain reaction (Q -RT-PCR: real time-reverse transcription polymerase chain reaction). Gene expression pattern changes were evaluated by real-time PCR using Applied Biosystems' TaqMan gene expression system (TaqMan gene expression assay kit, Applied Biosystems, Foster City, CA), and the results were evaluated by real-time PCR [Fig. 2A] To [Fig. 2d]. Both Q-RT-PCR and real-time PCR used were performed according to the standard protocol distributed by Life Technology, and specifically, after treatment at 95°C for 20 seconds, processing at 95°C for 3 seconds and 60°C for 30 seconds Was performed for 40 cycles.

As shown in [Fig. 2a] to [Fig. 2d], there is a gene whose expression level is increased in skin cells stimulated by inflammation or aging stimulation, and interleukin 1 alpha (IL-1a) by treatment with peppermint extract, It was confirmed that the expression levels of interleukin 1 beta (IL-1B), prostagladin-endoperoxide synthase 2 (PTGS2), and xanthine dehydrogenase (XDH) genes were reduced.

Therefore, the peppermint extract effectively protects skin cells from damage to skin cells caused by inflammation or aging stimulation, and inhibits or prevents changes in the expression level of the aforementioned specific genes due to the inflammation or aging stimulation, You can see that you can have.

Hereinafter, examples of the formulation of the composition according to the present invention will be described, but cosmetic compositions, pharmaceutical compositions, and health functional food compositions can be applied in various formulations, which are not intended to limit the present invention, but are intended to be described in detail .

[Formulation Example 1] Tablet

After mixing 100 mg of peppermint extract, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate according to an embodiment of the present invention, tablets were prepared by tableting according to a conventional tablet preparation method.

Ingredients Content(mg) Peppermint extract 100 Lactose 400 Corn starch 400 Magnesium stearate 2

[Formulation Example 2] Capsule

After mixing 100 mg of peppermint extract, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate according to an embodiment of the present invention, the capsules were prepared by filling them in gelatin capsules according to a conventional capsule preparation method.

Ingredients Content(mg) Peppermint extract 100 Lactose 400 Corn starch 400 Magnesium stearate 2

[Formulation Example 3] Granules

50 mg of peppermint extract according to an embodiment of the present invention, 250 mg of anhydrous crystalline glucose, and 550 mg of starch were mixed, molded into granules using a fluid bed granulator, and then filled into a cloth.

Ingredients Content(mg) Peppermint extract 50 Anhydrous glucose 250 Starch 550

[Formulation Example 4] Soap

Ingredients content(%) Peppermint extract 5.00 maintain Appropriate amount Sodium hydroxide Appropriate amount Sodium chloride Appropriate amount Spices Appropriate amount Purified water Balance

[Formulation Example 5] Lotion

Ingredients content(%) Peppermint extract 5.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Water-soluble collagen (1% aqueous solution) 1.00 Sodium citrate 0.10 Citric acid 0.05 Licorice extract 0.20 1,3-butylene glycol 3.00 Purified water Balance

[Formulation Example 6] Cream

Ingredients content(%) Peppermint extract 3.00 Polyethylene glycol monostearate 2.00 Self-emulsifying type glycerin monostearate 5.00 Cetyl alcohol 4.00 Squalene 6.00 Glyceryl tri2-ethylhexanoate 6.00 Sphingoglycolipid 1.00 1.3-butylene glycol 7.00 Purified water Balance

[Formulation Example 7] Ointment

Ingredients content(%) Peppermint extract 5.00 Polyvinyl alcohol 13.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Lauroylhydroxyproline 1.00 Water-soluble collagen (1% aqueous solution) 2.00 1,3-butylene glycol 3.00 ethanol 5.00 Purified water Balance

[Formulation Example 8] Preparation of essence

Ingredients content(%) Peppermint extract 3.00 Hydroxyethylene cellulose (2% aqueous solution) 12.00 Xanthan gum (2% aqueous solution) 2.00 1,3-butylene glycol 6.00 Dark glycerin 4.00 Sodium hyaluronate (1% aqueous solution) 2.00 Purified water Balance

[Formulation Example 9] Health Food

Ingredients content Peppermint extract 2mg Vitamin A acetate 70μg Vitamin E 1.0mg Vitamin B1 0.13mg Vitamin B2 0.15mg Vitamin B6 0.5mg Vitamin B12 0.2μg Vitamin C 10mg Biotin 10μg Nicotinic acid amide 1.7mg Folic acid 50μg Calcium pantothenate 0.5mg Ferrous sulfate 1.75mg Zinc oxide 0.82mg Magnesium carbonate 25.3mg Potassium Phosphate Monobasic 15mg Dicalcium phosphate 55mg Potassium citrate 90mg Calcium carbonate 100mg Magnesium chloride 24.8mg

[Formulation Example 10] Health Drink

Ingredients content Peppermint extract 50mg Citric acid 1000mg oligosaccharide 100 g Taurine 1g Purified water Balance

Claims (14)

Contains the extract of Mentha Arvensis fermentation fermented by adding Acetobacter sp. microorganisms as an active ingredient, and applied to keratinocytes, IL-1a, IL- in keratinocytes. 1B, PTGS2, and inhibits XDH gene expression, a cosmetic composition for suppressing oxidation, loss of elasticity, keratinization, or wrinkle formation of the skin caused by the expression of the gene by fine dust.
Contains the extract of Mentha Arvensis fermentation fermented by adding Acetobacter sp. microorganisms as an active ingredient, and applied to keratinocytes, IL-1a, IL- in keratinocytes. 1B, PTGS2, and inhibiting XDH gene expression, a health functional food composition for inhibiting oxidation, loss of elasticity, keratinization, or wrinkle formation of the skin caused by the expression of the gene by fine dust.
Contains the extract of Mentha Arvensis fermentation fermented by adding Acetobacter sp. microorganisms as an active ingredient, and applied to keratinocytes, IL-1a, IL- in keratinocytes. An anti-inflammatory cosmetic composition resulting from the expression of the gene by fine dust, which suppresses 1B and PTGS2 gene expression.
Contains the extract of Mentha Arvensis fermentation fermented by adding Acetobacter sp. microorganisms as an active ingredient, and applied to keratinocytes, IL-1a, IL- in keratinocytes. 1B and PTGS2 gene expression suppressing, anti-inflammatory health functional food composition caused by the gene expression by fine dust.
The method according to any one of claims 1 to 4,
The extract of the peppermint fermented product is contained in an amount of 0.000001 to 30% by weight based on the total weight of the composition.
The method according to any one of claims 1 to 4,
The extract of the fermented peppermint is water, C ₁ -C ₆ anhydrous or water-containing lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform, and any one selected from the group consisting of hexane That is, the composition extracted with the above extraction solvent.
The method according to any one of claims 1 to 4,
The extract of the fermented peppermint is extracted from the fermented product of leaves of peppermint, composition.
delete The method according to any one of claims 1 to 4,
The Acetobacter genus ( Acetobacter sp. ) The microorganism is Acetobacter Aceti ( Acetobacter aceti ), the composition.
delete The method according to any one of claims 1 to 4,
The extract of the peppermint fermented product is administered in a dosage of 10 to 500 mg / kg / day, composition.
delete delete delete

Images